Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency (Central Diabetes Insipidus) and Healthy Controls - the OxyMAX Study
Phase: NA | Sponsor: University Hospital, Basel, Switzerland | Compound: MDMA
- Status
- recruiting
- Institution
- University Hospital, Basel, Switzerland
- Start date
- 2025-01-27
- End date
- 2026-12-01
- Registry ID
- NCT06789705
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.